SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies
- PMID: 33099809
- DOI: 10.1111/pai.13400
SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies
References
REFERENCES
-
- Al Mutairi F, Alfadhel M, Nashabat M, et al. Phenotypic and molecular spectrum of aicardi-goutieres syndrome: a study of 24 patients. Pediatr Neurol. 2018;78:35-40.
-
- de Carvalho LM, Ngoumou G, Park JW, et al. Musculoskeletal disease in MDA5-related type I interferonopathy: a mendelian mimic of Jaccoud's arthropathy. Arthritis Rheumatol. 2017;69(10):2081-2091.
-
- Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91-98.
-
- Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7(4):255-266.
-
- Biesen R, Demir C, Barkhudarova F, et al. Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. Arthritis Rheum. 2008;58(4):1136-1145.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources